Tetracyclin ( DrugBank: Tetracyclin )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
36	Epidermolysis bullosa	2

36. Epidermolysis bullosa

---

Clinical trials : 160 /  Drugs : 195 - (DrugBank : 47) / Drug target genes : 50 - Drug target pathways : 124

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00336154 (ClinicalTrials.gov)	March 3, 2006	12/6/2006	Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa	Randomised Double Blind Crossover Placebo Controlled Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa	Epidermolysis Bullosa	Drug: tetracyclin	Rambam Health Care Campus	NULL	Withdrawn	13 Years	60 Years	All	0	Phase 4	Israel
2	EUCTR2010-024428-10-FR (EUCTR)		03/02/2011	Traitement des épidermolyses bulleuses simples de type Dowling Maera par l'érythromicine orale	Traitement des épidermolyses bulleuses simples de type Dowling Maera par l'érythromicine orale	Dowling Maera's bullous epidermolysis is a génodermatose with autosomique dominant transmission owed to transfers of the genes coding for keratins. It results from it a cutaneous fragility very severe especially during the early childhood. Tetracyclines showed a certain efficiency in cases isolated probably by their anti-inflammatory action but cannot be used at the young child's. The érythromycine, used in the other inflammatory dermatosis, seems to be a good candidate for these patients. MedDRA version: 12.1;Level: LLT;Classification code 10056508;Term: Acquired epidermolysis bullosa	Trade Name: erythrocine Product Name: erythrocine oral Trade Name: erythromycine Product Name: erythrocine oral	CHU de NICE	NULL	NA			Female: yes Male: yes	8	Phase 2	France